9 Meters Biopharma and Cara Therapeutics tout mid-stage data for gastrointestinal, pruritus studies
While 9 Meters Biopharma is still floundering in the penny stock market, the company is hoping the latest results for its candidate to treat short bowel syndrome, or SBS, can put together some positive momentum.
The company today announced preliminary topline results from its Phase II VIBRANT study. Its candidate, vurolenatide, is a long-acting GLP-1 receptor agonist in development for the treatment of adult patients with SBS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.